MX2012007783A - Compuestos sulfona que actuan como ligandos del receptor 5-ht6. - Google Patents

Compuestos sulfona que actuan como ligandos del receptor 5-ht6.

Info

Publication number
MX2012007783A
MX2012007783A MX2012007783A MX2012007783A MX2012007783A MX 2012007783 A MX2012007783 A MX 2012007783A MX 2012007783 A MX2012007783 A MX 2012007783A MX 2012007783 A MX2012007783 A MX 2012007783A MX 2012007783 A MX2012007783 A MX 2012007783A
Authority
MX
Mexico
Prior art keywords
receptor ligands
compounds
sulfone compounds
polymorphs
tautomers
Prior art date
Application number
MX2012007783A
Other languages
English (en)
Inventor
Rama Sastri Kambhampati
Venkateswarlu Jasti
Anil Karbhari Shinde
Ramakrishna Nirogi
Ishtiyaque Ahmad
Rajesh Kumar Badange
Veena Reballi
Anil Kashinath Chindhe
Rambabu Namala
Mohamad Sadik Abdulhamid Mulla
Renny Abraham
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MX2012007783A publication Critical patent/MX2012007783A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

La presente invención se relaciona con nuevos compuestos sulfona que actúan como ligandos del receptor 5-HT6 y que tienen la fórmula (I) y con sus derivados, profármacos, tautómeros, estereoisómeros, polimorfos, solvatos, hidratos, metabolitos, N-óxidos, sales farmacéuticamente aceptables y composiciones que las contienen. La presente invención también se relaciona con un proceso para la preparación de los nuevos compuestos mencionados y de sus derivados, profármacos, tautómeros, estereoisómeros, polimorfos, solvatos, hidratos, metabolitos, N-óxidos, sales farmacéuticamente aceptables y composiciones que las contienen. Estos compuestos son útiles en el tratamiento/ prevención de varios trastornos que están relacionados con las funciones del receptor 5-HT6.
MX2012007783A 2010-01-05 2010-03-24 Compuestos sulfona que actuan como ligandos del receptor 5-ht6. MX2012007783A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN18CH2010 2010-01-05
PCT/IN2010/000176 WO2011083487A1 (en) 2010-01-05 2010-03-24 Sulfone compounds as 5-ht6 receptor ligands

Publications (1)

Publication Number Publication Date
MX2012007783A true MX2012007783A (es) 2012-10-03

Family

ID=42941911

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007783A MX2012007783A (es) 2010-01-05 2010-03-24 Compuestos sulfona que actuan como ligandos del receptor 5-ht6.

Country Status (18)

Country Link
US (1) US9018231B2 (es)
EP (1) EP2521714B1 (es)
JP (1) JP5628937B2 (es)
KR (1) KR101463190B1 (es)
CN (1) CN102869647B (es)
AU (1) AU2010340745B2 (es)
BR (1) BR112012016526A2 (es)
CA (1) CA2786072C (es)
DK (1) DK2521714T3 (es)
EA (1) EA022043B1 (es)
ES (1) ES2552463T3 (es)
HK (1) HK1176619A1 (es)
IL (1) IL220709A (es)
MX (1) MX2012007783A (es)
NZ (1) NZ601284A (es)
SG (1) SG181992A1 (es)
WO (1) WO2011083487A1 (es)
ZA (1) ZA201205253B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3718547A1 (en) 2011-10-03 2020-10-07 The University of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
TWI623520B (zh) * 2012-12-12 2018-05-11 德商拜耳作物科學股份有限公司 製備雙（３－胺基苯基）二硫化物及３－胺基硫醇之方法
US20160038484A1 (en) * 2013-04-03 2016-02-11 The University Of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
CN105541693B (zh) 2014-07-08 2018-10-16 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
MA45002B1 (fr) 2016-05-18 2020-10-28 Suven Life Sciences Ltd Triple combinaison d'antagonistes purs du récepteurs 5-ht6, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteur nmda

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
US6316450B1 (en) 1997-07-11 2001-11-13 Smithkline Beecham P.L.C. Compounds
GB9801392D0 (en) 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9803411D0 (en) 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
JP4597386B2 (ja) 1999-04-21 2010-12-15 エヌピーエス ファーマシューティカルス，インコーポレーテッド ５−ｈｔ６親和性を有するピペリジン−インドール化合物
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
JP2004517058A (ja) * 2000-10-30 2004-06-10 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー アミノアルキルピロリジンセロトニン受容体リガンドおよび組成物、その医薬的使用およびその合成方法
AU2002236730B2 (en) 2001-01-30 2006-06-15 Eli Lilly And Company Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-HT6 receptor
WO2002098878A1 (en) 2001-02-08 2002-12-12 Memory Pharmaceuticals Corporation Trifluoromethylpurines as phosphodiesterase 4 inhibitors
ATE353318T1 (de) 2001-06-07 2007-02-15 Hoffmann La Roche Neue indolderivate mit affinität zum 5-ht6- rezeptor
JP2005528587A (ja) 2002-02-01 2005-09-22 バイエル・ヘルスケア・アクチェンゲゼルシャフト 新規ヒト５−ｈｔ６受容体に関連する疾患のための診断用および治療用物質
EP1471912A1 (en) 2002-02-05 2004-11-03 Glaxo Group Limited Method of promoting neuronal growth
WO2003080580A2 (en) 2002-03-27 2003-10-02 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
CA2507505C (en) 2002-11-28 2011-10-04 Suven Life Sciences Limited N-arylsulfonyl-3-aminoalkoxyindoles
AU2003237599B2 (en) 2002-11-28 2009-06-18 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
WO2004048331A1 (en) 2002-11-28 2004-06-10 Suven Life Sciences Limited N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands
WO2004108671A1 (en) 2003-06-06 2004-12-16 Suven Life Sciences Limited Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
WO2005066157A1 (en) 2004-01-02 2005-07-21 Suven Life Sciences 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators
WO2007020653A1 (en) * 2005-08-12 2007-02-22 Suven Life Sciences Limited Thioether derivatives as functional 5-ht6 ligands
SI1919896T1 (sl) * 2005-08-12 2010-04-30 Suven Life Sciences Ltd Aminoaril sulfonamidni derivati kot funkcionalni 5-HT6 ligandi
WO2007046112A1 (en) 2005-10-19 2007-04-26 Suven Life Sciences Inc. Arylthioether tryptamine derivatives as functional 5-ht6 ligands
WO2007138611A1 (en) * 2006-05-30 2007-12-06 Suven Life Sciences Limited 3-(heterocyclyl)-n-(arylsulfonyl)indole derivatives as functional 5-ht6 ligands

Also Published As

Publication number Publication date
CA2786072A1 (en) 2011-07-14
ZA201205253B (en) 2013-05-29
WO2011083487A1 (en) 2011-07-14
ES2552463T3 (es) 2015-11-30
EA201290610A1 (ru) 2013-02-28
CN102869647B (zh) 2015-06-24
CA2786072C (en) 2014-10-28
DK2521714T3 (en) 2015-10-19
KR101463190B1 (ko) 2014-11-18
EP2521714A1 (en) 2012-11-14
BR112012016526A2 (pt) 2018-11-06
HK1176619A1 (en) 2013-08-02
IL220709A (en) 2015-03-31
NZ601284A (en) 2014-03-28
US20130005709A1 (en) 2013-01-03
EP2521714B1 (en) 2015-08-12
US9018231B2 (en) 2015-04-28
JP2013516458A (ja) 2013-05-13
SG181992A1 (en) 2012-08-30
AU2010340745A1 (en) 2012-08-09
KR20120112726A (ko) 2012-10-11
CN102869647A (zh) 2013-01-09
AU2010340745B2 (en) 2014-11-20
EA022043B1 (ru) 2015-10-30
IL220709A0 (en) 2012-08-30
JP5628937B2 (ja) 2014-11-19

Similar Documents

Publication Publication Date Title
EA201490807A1 (ru) Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
TW200833675A (en) Nicotinamide derivatives
MX2013005535A (es) Compuesto de 3- (amino-aril) -piridina.
MX363127B (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
MX351305B (es) Antagonistas del receptor de mineralocorticoides.
MX2013003036A (es) Derivados de pirazina como bloqueadores de enac.
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
MX337721B (es) Compuestos de heteroarilo como ligandos del receptor 5-ht4.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX2012006909A (es) LIGANDOS DEL RECEPTOR NICOTINICO NEURONAL A4ß2 DE ACETILCOLINA.
MX2012002997A (es) Derivados de eter de los heteroarilos biciclicos.
MX2012000231A (es) Nuevos aza-biciclo-hexanos.
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
MX2012002608A (es) Compuesto 1,2-dihidro -2-oxoquinolona como ligandos del receptor 5ht4.
MX339858B (es) Compuestos novedosos como ligandos del receptor h3 de la histamina.
IN2013MN02170A (es)
MX2012007783A (es) Compuestos sulfona que actuan como ligandos del receptor 5-ht6.
MX2013006768A (es) Moduladores de receptor de glucagon.
EA201270556A1 (ru) Конденсированные тиазоло и оксазолопиримидиноны
EA201290344A1 (ru) БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ЛИГАНДОВ αβНИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА
MX2013001988A (es) Compuestos de heterociclilo comoligandos del receptor h3 de la histamina
MX2010007929A (es) Imidazolinilmetil aril sulfonamidas novedosas.
MX2014000855A (es) Moduladores receptores de glucagon de quinolinilo.

Legal Events

Date Code Title Description
FG Grant or registration